The impact of changed treatment patterns in multiple myeloma on health-care utilisation and costs, myeloma complications, and survival: A population-based comparison between two time periods in Denmark

被引:5
|
作者
Hannig, Louise Hur [1 ,2 ]
Nielsen, Lene Kongsgaard [1 ,3 ]
Ibsen, Rikke [4 ]
Arnheim-Dahlstrom, Lisen [5 ]
Kjellberg, Jakob [6 ]
Abildgaard, Niels [1 ,7 ,8 ]
机构
[1] Odense Univ Hosp, Dept Haematol, Odense, Denmark
[2] Vejle Hosp, Dept Internal Med, Beriderbakken 4, DK-7100 Vejle, Denmark
[3] Reg Hosp Viborg, Dept Internal Med & Cardiol, Viborg, Denmark
[4] I2minds, Aarhus, Denmark
[5] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[6] VIVE, Copenhagen, Denmark
[7] Univ Southern Denmark, Haematol Res Unit, Odense, Denmark
[8] Odense Univ Hosp, Acad Geriat Canc Res, Odense, Denmark
关键词
health‐ care costs; Multiple myeloma; retrospective; survival;
D O I
10.1111/ejh.13615
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate health-care utilisation and costs, myeloma complications and survival in Danish patients with multiple myeloma (MM) before and after implementation of new early-line treatments in 2009. Methods Based on data from the Danish National Health Registers, 3518 patients diagnosed with MM during 2002-2005 or 2010-2013 and randomly matched control individuals were identified, and health-care utilisation and costs were estimated. Results Health-care utilisation showed a marked shift from inpatient admissions towards outpatient visits. From early to late period, the mean annual number of outpatient visits increased by 22% and 28% in patients <65 years and >= 65 years, respectively. Additionally, the mean annual outpatient service costs increased correspondingly from 17 001euro to 23 643euro in younger patients and from 11 317euro to 16 144euro in the elderly. Increasing outpatient costs were outbalanced by lower inpatient admission costs and the adjusted total mean annual costs decreased in younger patients, probably partly due to fewer myeloma complications. The five-year survival rates increased markedly in both younger (HR = 0.51) and elderly (HR = 0.69) patients. Conclusion Despite the introduction of new expensive early-line MM treatments in 2009, health-care costs remained stable due to a shift in health-care utilisation towards outpatient clinic care and fewer complications.
引用
收藏
页码:63 / 73
页数:11
相关论文
共 6 条
  • [1] HEALTH CARE RESOURCE UTILIZATION PATTERNS IN FINNISH MULTIPLE MYELOMA PATIENTS: A POPULATION-BASED COHORT STUDY
    Metsa, R.
    Kosunen, M.
    Ruotsalainen, J.
    Purmonen, T.
    Raittinen, P.
    Kallio, A.
    VALUE IN HEALTH, 2023, 26 (12) : S507 - S507
  • [2] The impact of marginalization on treatment receipt and overall survival in newly diagnosed multiple myeloma patients in Ontario: a population-based cohort study
    Visram, Alissa
    Seow, Hsien
    Fiala, Mark
    Gayowsky, Anastasia
    Pond, Gregory
    Mian, Hira
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S25 - S26
  • [3] The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center
    Evans, Laura A.
    Go, Ronald
    Warsame, Rahma
    Nandakumar, Bharat
    Buadi, Francis K.
    Dispenzieri, Angela
    Dingli, David
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Kapoor, Prashant
    Leung, Nelson
    Fonder, Amie
    Hobbs, Miriam
    Hwa, Yi Lisa
    Muchtar, Eli
    Kourelis, Taxiarchis, V
    Russell, Stephen
    Lust, John A.
    Lin, Yi
    Siddiqui, Mustaqeem
    Kyle, Robert A.
    Gertz, Morie A.
    Rajkumar, S. Vincent
    Kumar, Shaji
    Gonsalves, Wilson, I
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (07): : 451 - +
  • [4] Real-world treatment patterns, outcomes, and economic costs by lines of therapy in patients with newly diagnosed multiple myeloma: a nationwide population-based cohort study in South Korea
    Sung-Soo Park
    YoungJu Park
    Soomin Yoon
    Doik Lee
    Jihyeon Jeong
    Kihyun Kim
    Blood Research, 2025, 60 (1)
  • [5] RESOURCE UTILISATION AND RELATED HEALTH CARE COSTS AMONG PATIENTS WITH MULTIPLE MYELOMA WITH ≥ 2 PRIOR LINES OF TREATMENT IN FINLAND: EVALUATION BASED ON FINNISH REAL WORLD DATA FROM AURIA BIOBANK
    Kosunen, M.
    Kurki, S.
    Snicker, K.
    Wiik, E.
    VALUE IN HEALTH, 2017, 20 (09) : A498 - A499
  • [6] Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004*
    Vangsted, Annette J.
    Klausen, Tobias W.
    Andersen, Niels F.
    Abildgaard, Niels
    Gang, Anne O.
    Gregersen, Henrik
    Vogel, Ulla
    Gimsing, Peter
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 85 (03) : 209 - 216